



Q1 FY2027 Earnings Results

August 3, 2026
Kitazato Corporation

Summary of Q1 FY2027 Financial Results



Financial Highlights for 1Q FY2027

Net Sales: JPY3.0bn (+24%; JPY2.4bn in 1Q FY2026)

- Japan: Increased 11%, driven by solid one-off orders prompted by concerns over geopolitical tensions in the Middle East.
- Overseas: Increased 32%, led by Europe, the U.S., and other regions.
- Products: Sales increased across all product categories.


Net Income: JPY1.0bn (+35%; JPY0.7bn in 1Q FY2026)

- Gross Profit: Increased 20% mainly due to an increase in net sales, partly offset by the higher cost ratio due to a change in the product mix.
- Operating Profit: Increased 27%, reflecting higher gross profit and slightly lower SG&A expenses.
- Ordinary Profit: Increased 37%, reflecting foreign exchange gains and the absence of listing-related expenses recorded in 1Q FY2026.


Net Sales




Gross Profit




Operating Profit




Operating Profit Margin



Overseas Sales Ratio



Equity Ratio



* Comparisons are year on year.

Operating Results

- Net sales amounted to JPY3,017m (+24.0%), while operating profit amounted to JPY1,517m (+27.0%).
- The cost of sales ratio was 37.5% (+2.0%), while the SG&A expense ratio improved to 12.2% (−3.1%), resulting in a 1.2% improvement in the operating profit margin.

(JPY million)

	FY2026	FY2027				
	1Q Actual (A)	1Q Actual (B)	Change (B-A)	YoY (B/A)	Full-Year Forecast (C)	1Q Progress (B/C)
Net Sales	2,434	3,017	583	24.0%	11,346	26.6%
Cost of Sales	865 (35.5%)	1,131 (37.5%)	265	30.7%	3,767 (33.2%)	30.0%
SG&A Expenses	373 (15.3%)	368 (12.2%)	-5	-1.4%	1,463 (12.9%)	25.2%
Operating Profit	1,195 (49.1%)	1,517 (50.3%)	322	27.0%	6,115 (53.9%)	24.8%
Quarterly Net Income	745 (30.6%)	1,007 (33.4%)	261	35.1%	4,059 (35.8%)	24.8%

* Comparisons are year on year. Figures in parentheses indicate the ratio to net sales.

Net Sales by Region

- Net sales in Japan: JPY993m (+10.9%); overseas net sales: JPY2,024m (+31.6%).
- The overseas sales ratio increased to 67.1%, an improvement of 3.9%.

(JPY million)

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
Net Sales	2,434	10,947	3017	24.0%	11,346	26.6%
Japan	895	3,660	993	10.9%	3,691	26.9%
Overseas	1,538	7,287	2,024	31.6%	7,655	26.4%
Europe	844	3,990	1,135	34.5%	4,215	26.9%
U.S.	242	1,120	317	30.8%	1,205	26.3%
China	133	672	126	-5.0%	700	18.1%
India	145	593	154	6.2%	593	26.0%
Other	173	909	290	67.9%	941	30.9%


* Comparisons are year on year.

■ Net sales increased, supported by strengthened sales activities, including more frequent customer visits, as well as one-off orders placed due to concerns over geopolitical tensions in the Middle East.

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
Japan	895	3,660	993	10.9%	3,691	26.9%

Net Sales Trend


(JPY million)



Net Sales by Region (Europe)

■ Sales increased as we continued to acquire new customers while sales to existing customers also expanded.

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
Europe	844	3,990	1,135	34.5%	4,215	26.9%




Net Sales by Region (United States)

■ Sales remained solid across all product categories.


	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
U.S.	242	1,120	317	30.8%	1,205	26.3%

Net Sales Trend (JPY million)



■ Net sales decreased due to the postponement of certain shipments, while underlying sales remained solid.

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
China	133	672	126	-5.0%	700	18.1%
Net Sales Trend (JPY million)						




Net Sales by Region (India)

■ The impact of changes to the sales structure was limited, and sales remained solid.

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
India	145	593	154	6.2%	593	26.0%

Net Sales Trend (JPY million)




Net Sales by Product Category

■ Net sales increased year on year across all product categories. (million yen)

	FY2026		FY2027			
	1Q Actual	Full-Year Actual	1Q Actual	YoY	Full-Year Forecast	1Q Progress
Net Sales	2,434	10,947	3,017	24.0%	11,346	26.6%
Media	923	4,004	1,071	16.0%	4,157	25.8%
Cryodevice	563	3,081	810	43.7%	3,191	25.4%
Medical Devices	606	2,512	707	16.5%	2,620	27.0%
Micro Tools	282	1,099	362	28.0%	1,122	32.3%
Other	56	249	66	17.3%	253	26.2%

Ordinary Profit Bridge (YoY)



■ Ordinary profit increased by JPY410m year on year to JPY1,535m.



- (JPY million)
- Gross Profit : +317
 - Advertising Expenses : +27
 - Depreciation and Amortization : -8
 - Other SG&A Expenses : -14
 - Listing-related Expenses : +49
 - Foreign Exchange Gain : +33
 - Other Non-operating Income : +4

■ As of the end of 1Q FY2027, the equity ratio improved to 94.6% from 93.2% at the end of FY2026.

(JPY million)

Total Assets

Liabilities and Net Assets



Consolidated Earnings Forecast for FY2027

■ There is no change to the earnings forecast announced on April 30, 2026.

(JPY million)

	2026.3 Actual	2027.3 Plan	YoY Change
Net Sales	10,947	11,346	3.6%
Operating Profit	5,858	6,115	4.4%
Operating Margin	53.5%	53.9%	0.4pt
Ordinary Profit	5,903	6,137	4.0%
Ordinary Margin	53.9%	54.1%	0.2pt
Net Income	3,895	4,059	4.2%
Net Income Margin	35.6%	35.8%	0.2pt

Kitazato Challenge 2036



KITAZATO®

“Happiness, for the Next Generations”


We contribute to improving healthcare so that patients can undergo fertility treatment while maintaining their well-being, and to creating a social environment where children can grow up healthy.

Our Initiatives in Clinical Practice

				
Research and Development to Improve Pregnancy Outcomes	Reducing Treatment Costs Through Affordable Media and Consumables	Technical Training and Scientific Support for Healthcare Professionals	Promoting Patient Understanding of Fertility Treatment	Supporting Healthcare Collaboration from Fertility Treatment to Obstetrics and Pediatrics

Public Policy and Social Initiatives

				
Enhanced Financial Support Programs	Expansion of Childcare and Educational Services	Support for Balancing Work and Childcare	Development of Housing and Community Infrastructure	Marriage Support and Public Awareness Initiatives




Contribute to addressing social challenges such as declining birth rates and population through fertility treatment

Create a society in which people can pursue parenthood while maintaining their well-being

Kitazato Challenge 2036

Expand new businesses and M&A while strengthening our core business
Execute a three-stage growth strategy over the 10-year period from FY2027 to FY2036



Progress of Stage 1 "Challenge"

18

Strengthening Our Core Businesses While Exploring New Growth Areas

FY2029 Net Sales Target

JPY33.3 billion

Core Businesses: JPY13.3 billion +
New Businesses: JPY20.0 billion

Expand

- Strengthen the sales, manufacturing, and development functions of existing fertility treatment products
- Reduce costs, improve product mix, and expand overseas sales

Explore

- Explore opportunities in pharmaceuticals, IVD, CryoBank, AI, and clinic collaboration
- Evaluate new business opportunities through M&A, strategic alliances, and joint ventures

Progress

- **Company Name Change**
Changed the Japanese company name to "Kitazato," unifying the brand name used in Japan and overseas to support global brand development.
- **Launch of a New Product**
Launched Hypure® Oil, a new product utilizing our proprietary patented technology.
- **Acquisition of Intellectual Property Rights**
Received a decision to grant a Japanese patent for a pelvic floor muscle support device.
- **Introduction of Automated Manufacturing Equipment for Oocyte Retrieval Needles**
Automated the assembly process for oocyte retrieval needles, contributing to unmanned operation, higher productivity, and improved product quality.
- **Establishment of a Joint Venture in India**
Strengthening sales promotion, customer support, and technical support capabilities in the Indian market.
- **Collaboration with SIOS Technology, Inc.**
Commenced joint development of new AI-powered products.

+ Kitazato Smile Initiative

Donations to the J.POSH Scholarship Fund and the Pink Ribbon Fund

Made donations to support breast cancer patients and children who will lead the next generation.

Some of the information contained in this document includes statements regarding future performance. These statements do not guarantee future performance and involve risks and uncertainties. Please note that actual results may differ from these statements due to changes in the business environment and other factors.

This material is an English translation of the original Japanese-language material. In the event of any discrepancy between the English and Japanese versions, the Japanese version shall prevail.

Contact Information

Kitazato Corporation

Corporate Planning Department

TEL +81-545-65-7122

URL <https://www.kitazato.co.jp/en/ir/inquiry/>



www.kitazato.co.jp